COX-2: A protein with an active role in gynecological cancers

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 1, 2005, Pages 49-53

  Munkarah, Adnan ^a   Ali Fehmi, Rouba ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

COX 2; Gynecological cancer; Prevention

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EXEMESTANE; PACLITAXEL; TRASTUZUMAB;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 14644440823     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200502000-00009     Document Type: Review

References (36)

1. Vane J. Towards a better aspirin. Nature 1994; 367: 215-216.
2. DuBois RN, Awad J, Morrow J, et al. Regulation ol eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-a and phorbol ester J Clin Invest 1994; 93:493-498.
3. Kujubu DA, Fletcher BS, Varnum BS, et al. TS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-12872.
4. Chen G, Wilson R, McKillop JH, Walker JJ. The role of cytokines in the production of prostacyclin and thromboxane in human mononuclear cells. Immunol Invest 1994; 223:269-279.
5. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin and hormone receptor status with breast cancer risk. JAMA 2004; 291:2433-2440. A large population-based case-control study that analyses the effects of various analgesics use on the incidence of invasive and in-situ breast cancer, with special emphasis on the frequency and duration of drug intake.
6. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-sterodial anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003; 14:915-922. A population-based case-control study that confirms previous studies and shows a strong protective effect for both prescription and non-prescription NSAIDs against invasive breast cancer.
7. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88:1687-1692. A large population-based study that investigates the effects of non-aspirin NSAID intake on the risk of developing cancer, and confirms their protective effect against gastrointestinal, breast and ovarian cancers.
8. Lacey JV, Sherman ME, Hartge P, et al. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004; 108:281-286. A large epidemiological study that fails to confirm the protective effect of NSAIDs against ovarian cancer.
9. O'Connor JK, Avent J, Lee RJ, et al. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Bio Phys 2004; 58:1034-1040. This study that includes a small number of patients confirms the significant impact that COX-2 expression has on prognosis in patients with invasive breast cancer.
10. 2 secretion in patients with breast cancer. Ann Surg Oncool 2004; 11:328-339. The authors try to explore the question of immunosuppression in breast cancer and its association with COX-2 expression and prostaglandin production. The study is descriptive but the findings are very interesting and support the hypothesis that COX-2 expression contributes to tumor progression by interfering with immune surveillance.
11. Tan KB, Yong WP, Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2004; 44:24-28. A study confirming that COX-2 is overexpressed in DCIS and that overexpression correlates with a high nuclear grade.
12. Boland GP, Butt IS, Prasad R, et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004; 90:423-429. A nicely designed study comparing COX-2 expression n DCIS, invasive breast cancer and normal breast tissue and correlating this expression with surrogate markers of aggressive DCIS phenotype.
13. Ali-Fehmi R, Che M, Khalifeh I, et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003; 98:1423-1429. A large retrospective study investigating the patterns of COX-2 expression and its association with various molecular markers and tumor vascularity in ovarian cancer. The strengths of the study lie in the large patient population and its homogeneity with respect to tumor histology and stage.
14. Khalifeh I, Munkarah AR, Loonardo F, et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. J Gynecol Pathol 2004; 23:162-169.
15. Seo SS, Song YS, Kang DH, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 2004; 92:927-935. This study looks at the patterns COX-2 expression in the various epithelial ovarian cancer histological variants, and correlates expression with clinical characteristics.
16. Raspollini MR, Amunni G, Villanucci A, et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 2004; 92:806-812.
17. Li S, Miner K, Fannin R, et al. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 2004; 92:622-627. A very good study investigating COX-1 and COX-2 expression in primary and metastatic epithelial ovarian cancer and comparing it to normal ovarian epithelium. It also addresses the possible effects of COX-2 expression with respect to local invasion and distant metastasis.
18. Raspollini MR, Amunni G, Villanucci A, et al. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. Oncol Rep 2004; 11:309-313. An interesting study confirming the correlation between COX-2 expression and tumor angiogenesis in ovarian cancer and the impact of these changes on patient survival.
19. Roland IH, Yang WL, Yang DH, et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphological changes in prophylactic oophorectomies. Cancer 2003; 98:2607-2623. A very important study that sheds some light on the preneoplastic changes that may lead to ovarian carcinogenesis. The authors link the COX-2 enzyme to these preneoplastic changes.
20. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:922-928. A retrospective study of patients with stage IB-IVA carcinoma of the cervix treated with radiation confirming the negative impact of COX-2 expression on disease-free survival.
21. Kim MH, Seo SS, Song YS, et al. Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 2003; 90:83-90. A well-designed study that investigates the expression of both COX isozymes, COX-1 and COX-2, in specimens obtained from a relatively large cohort of patients with cervical cancer (stage IB-IIB). It also tries to further our understanding about the COX biological effects by analysing the impact of such expression on local tumor progression and angiogenesis.
22. Ferrandina G, Ranelletti FO, Lauriola L, et al. Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer. Oncol Rep 2003; 10:1799-1804.
23. Parley J, Uyehara C, Hashiro G, et al. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol 2004; 92:596-602. An original paper investigating the role of COX-2 in pre-invasive cervical disease. The small number of cases precludes any definite conclusion and obviates the need for a similar study with a larger sample.
24. Cao QJ, Einstein MH, Anderson PS, et al. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 2002; 21:147-154.
25. Ferrandina G, Legge F, Ranelletti RO, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathological parameters and clinical outcome. Cancer 2002; 95:801-807.
26. Peek RMJ. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother Pharmacol 2004; e-published ahead of publication. Available at: Springerlink.metapress.com.
27. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003; 12:1486-1491. Elegantly designed experiments that prove the efficacy of COX-2 inhibitors in preventing breast cancer in Her-2/neu transgenic mice. The authors prove that treatment with celecoxib will delay the development of mammary tumors, decrease their numbers and prevent metastasis.
28. 2 contribute to tumor growth and progression by stimulating angiogenic factors and promoting angiogenesis in the mammary tissues.
29. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:447-451.
30. Ness RB, Goodman MT, Shen C, Brunham RC. Serologic evidence of past infection with Chlamydia trachomatis in relation to ovarian cancer. J Infect Dis 2003; 187:147-152. A good case-control study trying to confirm the association between pelvic inflammatory disease and ovarian cancer by measuring the titers of antichlamydia antibodies and comparing them in ovarian cancer cases and controls.
31. Borfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Obstet Gynecol Surv 2004; 59:510-511. A very interesting large case-control study showing an increase in ovarian cancer risk in women hospitalized for endometriosis. The authors also show an earlier age at cancer diagnosis in the endometriosis group.
32. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405-414. An important study that adds to our knowledge regarding the association between infertility and ovarian cancer. The authors note that the risk of developing ovarian cancer was highest in women with primary infertility and endometriosis.
33. Barnes MN, Chhieng D, Riaz V, et al. A controlled clinical trial of celecoxib as a chemopreventive agent in woman at elevated risk of ovarian carcinoma: SGO [abstract 16]. Gynecol Oncol 2004; 92:400.
34. Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 2004; 10:4062-4067. This phase II trial confirms the safety of combining celecoxib and the antiangiogenesis drug, trastuzumab, in a small group of breast cancer patients.
35. Munkarah AR, Genhai Z, Morris R, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 2003; 88:429-433.
36. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 2003; 9:4324-4331. The first pilot study to describe the molecular effects of treatment with a specifc COX-2 inhibitor in cervical cancer. The reduction in cellular proliferation and tumor vascularity observed with celecoxib treatment supports the need for larger trials investigating the therapeutic role of COX-2 inhibitors in this disease.